months
partners
countries
mio. €
Reflections from the First Year of IFIGENEIA
Progress, collaboration, and growing impact across science and society As the IFIGENEIA Project completes its first...
Did you know: Radiofarmaceuticals and the story behind them
Radiofarmaceuticals are a special type of medicine that use radioactive substances to diagnose or treat diseases,...
Meet the IFIGENEIA Partner: CERN, Conseil Européen pour la Recherche Nucléaire
Advancing accelerator science and knowledge transfer, CERN brings its world-leading expertise in particle physics and...
Our Goals
Implement Linear Accelerator (LINAC) technology in Europe to improve healthcare by
Designing sustainable facilities for radionuclide therapy, diagnostics, and theranostics
Establishing Centres of Excellence in Greece, Slovenia, and Cyprus to operate LINAC facilities that produce a wide range of medical radioisotopes
Strengthening collaboration between science, industry, and healthcare
IFIGENEIA is pioneering a new era in nuclear medicine with compact, efficient LINAC technology.
The project spans 6 countries—Greece, Slovenia, Cyprus, Bosnia and Herzegovina, Germany and Switzerland — uniting experts in science, medicine & culture.
IFIGENEIA will develop a design & business plan for a new LINAC facility in the Balkans.
The project includes creating Excellence Hubs focused on R&I, business, and societal impact.
IFIGENEIA is tapping into CERN’s advanced accelerator know-how to build local capacities.
IFIGENEIA follows the SMART objective model—Specific, Measurable, Achievable, Relevant, Time-related.
A major goal of IFIGENEIA? Secure long-term investment for isotope production hubs via public-private partnerships.
Isotope production isn't just for medicine—it's also used in archaeology, environmental studies & art preservation.
The IFIGENEIA links academia, government, industry & society in a true quadruple helix approach.
LINACs reduce reliance on highly enriched uranium, offering a safer, cleaner isotope supply.
IFIGENEIA aims to create at least one new patent in particle acceleration techniques.
Within IFIGENEIA, over 1500 citizens across 6 countries will be engaged through events and outreach by 2029.
With IFIGENEIA, a new EU-wide LINAC Cluster is in the making—linking national hubs for greater R&I impact.
IFIGENEIA project goes beyond health—LINACs will aid in analysing ancient artefacts.
IFIGENEIA includes training, secondments & good practice exchanges to build skills across regions.
10+ scientific IFIGENEIA papers will be submitted, and an international event organised to share findings.
IFIGENEIA promotes regional innovation strategies (RIS3) aligned with EU goals.
Gender & diversity are at the core of IFIGENEIA —ensuring inclusive participation and analysis.
Public showcase IFIGENEIA events will open demo sites for citizens, students & agencies.
One key goal: Mobilise €6 million in public-private funding over 4 years.
IFIGENEIA will help establish new spin-offs and startups in nuclear tech fields.
By 2029, 300 stakeholders from academia, public bodies, business & society will be involved IN IFIGENEIA.
IFIGENEIA is not just a project—it’s a movement toward smarter, safer, more accessible nuclear healthcare.
IFIGENEIA will contribute to the creation of new high-skilled job positions in nuclear tech fields, while also attracting top researchers from abroad, reducing brain drain and fostering brain gain in the scientific sector.
Partners
Partners
